泓博医药股价跌5.02%，财通证券资管旗下1只基金重仓，持有50万股浮亏损失96万元

Group 1 - The core point of the news is that Hongbo Pharmaceutical experienced a decline of 5.02% in its stock price, reaching 36.33 yuan per share, with a trading volume of 214 million yuan and a turnover rate of 7.45%, resulting in a total market capitalization of 5.071 billion yuan [1] - Hongbo Pharmaceutical, established on December 14, 2007, and listed on November 1, 2022, is located in Shanghai and focuses on drug discovery, pharmaceutical process research and development, and the commercial production of active pharmaceutical ingredients. The revenue composition is as follows: drug discovery 52.67%, commercial production 35.00%, process research and development 8.10%, and others 4.23% [1] Group 2 - From the perspective of major fund holdings, one fund under Caitong Securities Asset Management holds a significant position in Hongbo Pharmaceutical. The Caitong Asset Management Health Industry Mixed A Fund (012159) held 500,000 shares in the second quarter, accounting for 4.15% of the fund's net value, ranking as the tenth largest holding. The estimated floating loss today is approximately 960,000 yuan [2] - The Caitong Asset Management Health Industry Mixed A Fund (012159) was established on November 23, 2021, with a current scale of 158 million yuan. Year-to-date, it has achieved a return of 41.31%, ranking 1049 out of 8179 in its category; over the past year, it has returned 58.21%, ranking 1986 out of 7984; and since inception, it has returned 24.18% [2]